On Tuesday, PTC Therapeutics earned an upgrade to its Relative Strength (RS) Rating, from 90 to 95.
This unique rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of above 80 as they launch their biggest runs.
How To Use Stock Charts To Stay Profitable And Protected
PTC Therapeutics is now considered extended and out of buy range after clearing a 40.69 buy point in a second-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
PTC Therapeutics showed 0% EPS growth last quarter, while sales growth came in at 0%.
PTC Therapeutics holds the No. 73 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
